Zoetis Inc. (NYSE:ZTS) to Post Q2 2024 Earnings of $1.46 Per Share, William Blair Forecasts

Zoetis Inc. (NYSE:ZTS) – Analysts at William Blair lowered their Q2 2024 EPS estimates for Zoetis in a note issued to investors on Thursday, May 2nd. William Blair analyst B. Vazquez now anticipates that the company will post earnings per share of $1.46 for the quarter, down from their prior estimate of $1.49. The consensus estimate for Zoetis’ current full-year earnings is $5.77 per share. William Blair also issued estimates for Zoetis’ Q3 2024 earnings at $1.48 EPS, Q4 2024 earnings at $1.43 EPS, FY2024 earnings at $5.76 EPS, Q1 2025 earnings at $1.53 EPS, Q2 2025 earnings at $1.64 EPS, Q3 2025 earnings at $1.66 EPS, Q4 2025 earnings at $1.61 EPS and FY2025 earnings at $6.43 EPS.

Zoetis (NYSE:ZTS) last issued its quarterly earnings results on Thursday, May 2nd. The company reported $1.38 EPS for the quarter, topping the consensus estimate of $1.34 by $0.04. The business had revenue of $2.19 billion for the quarter, compared to analysts’ expectations of $2.14 billion. Zoetis had a net margin of 27.38% and a return on equity of 50.34%. The company’s quarterly revenue was up 9.5% compared to the same quarter last year. During the same quarter last year, the company posted $1.31 earnings per share.

Several other equities analysts have also recently issued reports on the company. Barclays reduced their price objective on Zoetis from $260.00 to $230.00 and set an “overweight” rating on the stock in a research note on Tuesday, April 23rd. The Goldman Sachs Group decreased their price target on shares of Zoetis from $223.00 to $196.00 and set a “buy” rating for the company in a report on Monday. Stifel Nicolaus lowered their price objective on shares of Zoetis from $195.00 to $180.00 and set a “buy” rating for the company in a research report on Tuesday, April 30th. Piper Sandler reissued an “overweight” rating and issued a $195.00 target price (down previously from $220.00) on shares of Zoetis in a report on Tuesday, April 16th. Finally, StockNews.com lowered Zoetis from a “strong-buy” rating to a “buy” rating in a report on Tuesday, February 20th. Eight analysts have rated the stock with a buy rating, Based on data from MarketBeat, Zoetis has a consensus rating of “Buy” and an average price target of $212.38.

Zoetis Trading Down 0.7 %

NYSE:ZTS opened at $165.95 on Monday. Zoetis has a 52 week low of $144.80 and a 52 week high of $201.92. The company has a quick ratio of 1.94, a current ratio of 3.33 and a debt-to-equity ratio of 1.30. The company has a market cap of $75.72 billion, a PE ratio of 31.98, a P/E/G ratio of 2.62 and a beta of 0.86. The business’s 50 day moving average is $168.25 and its two-hundred day moving average is $178.92.

Hedge Funds Weigh In On Zoetis

Hedge funds have recently modified their holdings of the stock. Hohimer Wealth Management LLC boosted its position in Zoetis by 1.2% during the fourth quarter. Hohimer Wealth Management LLC now owns 4,386 shares of the company’s stock worth $866,000 after purchasing an additional 52 shares during the period. Forum Financial Management LP boosted its holdings in shares of Zoetis by 0.8% during the 4th quarter. Forum Financial Management LP now owns 7,386 shares of the company’s stock worth $1,458,000 after buying an additional 56 shares during the period. Angeles Wealth Management LLC grew its stake in Zoetis by 3.5% in the 4th quarter. Angeles Wealth Management LLC now owns 1,640 shares of the company’s stock valued at $324,000 after buying an additional 56 shares during the last quarter. Prossimo Advisors LLC raised its holdings in Zoetis by 1.7% in the 4th quarter. Prossimo Advisors LLC now owns 3,498 shares of the company’s stock worth $690,000 after acquiring an additional 57 shares during the period. Finally, River Street Advisors LLC lifted its position in Zoetis by 3.4% during the 4th quarter. River Street Advisors LLC now owns 1,757 shares of the company’s stock worth $347,000 after acquiring an additional 58 shares during the last quarter. 92.80% of the stock is owned by institutional investors and hedge funds.

Insider Activity

In other news, EVP Roxanne Lagano sold 363 shares of Zoetis stock in a transaction that occurred on Monday, February 12th. The shares were sold at an average price of $197.74, for a total value of $71,779.62. Following the transaction, the executive vice president now directly owns 20,417 shares of the company’s stock, valued at $4,037,257.58. The transaction was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Insiders sold a total of 2,209 shares of company stock valued at $371,293 over the last three months. Insiders own 0.16% of the company’s stock.

Zoetis Company Profile

Zoetis Inc engages in the discovery, development, manufacture, and commercialization of animal health medicines, vaccines, and diagnostic products and services in the United States and internationally. The company commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep and others; and companion animals comprising dogs, cats, and horses.